Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.

Sir, Sexual transmission of HIV-1 is currently the major way of viral spread worldwide: the quantification of seminal HIV-1 RNA has been clearly linked to the risk of transmission. The use of highly active antiretroviral treatment, besides providing immunovirological benefits, has been associated with viral control in the genital compartment of males and females. Nevertheless, occasional HIV-1 ...

متن کامل

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

Current guidelines recommend three drug combinations to treat antiretroviral naïve HIV-infected patients; some data of novel strategies with NRTI-sparing regimen in this setting are now available [1,2]. The study compares immunovirological efficacy and safety of once daily maraviroc (MVC) plus lopinavir/ritonavir (LPV/r) to tenofovir/emtricitabine (TDF/FTC) plus LPV/r. This is an ongoing, proof...

متن کامل

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients

CONTEXT Once-daily HIV treatment regimens are being used in clinical practice with the objective of improving patient acceptance and adherence. OBJECTIVE To evaluate the efficacy and safety of saquinavir-soft-gelatin capsule (SGC)/ritonavir combination (1600 mg/100 mg) vs efavirenz (600 mg) both once daily and combined with 2 nucleoside analogs twice daily. SETTING Twenty-six centers in the...

متن کامل

Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.

and these results were considered the reference standard against which all other results were compared. Temocillin Etests were used according to the manufacturer's instructions. Susceptibility to temocillin using the Phoenix system was determined according to BSAC breakpoints for Enterobacteriaceae for systemic infections (susceptible if MIC ≤8 mg/L). 3 If the Etest or Phoenix results were with...

متن کامل

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.

BACKGROUND A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir. METHODS During this multicentre, open-label, Phase IIa trial, treatment-naive patients aged > or =18 years with HIV type-1 (HIV-1) received etravirine 400 mg once daily with tenofovir disoproxil fumarate/emtricitabine 300/200 mg ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Antimicrobial Chemotherapy

سال: 2014

ISSN: 0305-7453,1460-2091

DOI: 10.1093/jac/dku142